Health Canada Allows Start of DA01 Trial Testing Cell Therapy

Health Canada Allows Start of DA01 Trial Testing Cell Therapy

291484

Health Canada Allows Start of DA01 Trial Testing Cell Therapy

BlueRock Therapeutics has received permission from Health Canada to start a Phase 1 clinical trial evaluating DA01, an investigational cell therapy that aims to restore neurons lost to Parkinson’s disease. This clearance comes three months after the U.S. Food and Drug Administration (FDA) accepted the company’s request to launch the trial in the United States. “We’re excited to initiate this study with our expert collaborators at University Health Network in Toronto as we believe this…

You must be logged in to read/download the full post.